Merit Financial Group
VRTX icon

Merit Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Merit Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.04M Buy
13,460
+1,242
+10% +$636K 0.04% 376
2026
Q2 		$6.07M Buy
12,218
+1,883
+18% +$835K 0.04% 378
2026
Q1 		$4.62M Buy
10,335
+1,368
+15% +$638K 0.03% 412
2025
Q4 		$4.07M Buy
8,967
+2,880
+47% +$1.24M 0.03% 413
2025
Q3 		$2.38M Sell
6,087
-173
-3% -$72.3K 0.02% 506
2025
Q2 		$2.79M Buy
6,260
+833
+15% +$384K 0.03% 422
2025
Q1 		$2.63M Buy
5,427
+496
+10% +$231K 0.04% 354
2024
Q4 		$1.99M Buy
4,931
+2,155
+78% +$999K 0.04% 356
2024
Q3 		$1.29M Sell
2,776
-1,001
-27% -$481K 0.03% 356
2024
Q2 		$1.77M Buy
3,777
+342
+10% +$148K 0.04% 292
2024
Q1 		$1.38M Buy
3,435
+1,477
+75% +$624K 0.03% 333
2023
Q4 		$797K Sell
1,958
-1,698
-46% -$627K 0.02% 370
2023
Q3 		$1.27M Sell
3,656
-275
-7% -$96.2K 0.04% 283
2023
Q2 		$1.38M Buy
3,931
+2,297
+141% +$774K 0.04% 280
2023
Q1 		$515K Buy
+1,634
New +$490K 0.02% 394

Other funds holding VRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Merit Financial Group's VRTX Position: Q3 2026 in Review

Merit Financial Group increased its Vertex Pharmaceuticals (VRTX) stake by 10% in Q3 2026, buying an estimated $636K and bringing the position to 13,460 shares worth $7.04M. The position accounts for 0.04% of the portfolio, ranked #376.

Merit Financial Group first reported a position in VRTX in Q1 2023 and has held it in 15 quarters since. 992 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Merit Financial Group held 13,460 shares of Vertex Pharmaceuticals worth $7.04M as of Q3 2026.
  • Merit Financial Group bought 1,242 Vertex Pharmaceuticals shares in Q3 2026, an estimated $636K.
  • Vertex Pharmaceuticals made up 0.04% of Merit Financial Group's portfolio in Q3 2026, its #376 holding.
  • Merit Financial Group first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 15 quarters since.
  • 992 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Merit Financial Group's 13F filing for Q3 2026, filed 6 Nov 2026.